002020 Zhejiang Jingxin Pharmaceutical
- 11.30
- +0.15+1.35%
Zhejiang Jingxin Pharmaceutical News
Jingxin Pharmaceutical (002020.SZ): The artificial large blood vessel project has now entered the small-scale human trial stage
Gelonghui, May 30丨Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company's artificial large blood vessel project has now entered the small-scale human trial stage. The time to market also depends on the progress of testing and other related work.
Jingxin Pharmaceutical (002020.SZ): 2023 equity distribution 10 distribution 3 yuan share registration date May 23
On May 16, Ge Longhui Pharmaceutical (002020.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 3.00 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 861,029,140 shares. The share registration date for this equity distribution is May 23, 2024, and the ex-dividend date is May 24, 2024.
Jingxin Pharmaceutical (002020.SZ): Currently, production of some varieties of Shaxi Pharmaceutical is being transferred in an orderly manner to the new production area in Inner Mongolia
Gelonghui, May 8 | Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that Shaxi Pharmaceutical is unable to carry out effective renovation and expansion because the site and plant are not independent property rights. The company has built a new production base for traditional Chinese medicine in Beijing, Inner Mongolia, and trial production began in October last year. Currently, production of some varieties of Shaxi Pharmaceutical is being transferred in an orderly manner to new production areas in Inner Mongolia.
Jingxin Pharmaceutical (002020.SZ): There are no plans to expand Ruitai's investment
Gelonghui, May 8, 丨 Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company has no plans to expand Ruitai's investment.
Jingxin Pharmaceutical (002020.SZ): An Palace beef yellow pill was launched in the second half of 2022
Gelonghui, May 8 | Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company's Angong beef yellow pills were launched in the second half of 2022 and are currently not sold in JD and Tmall flagship stores.
Calculating The Intrinsic Value Of Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020)
Key Insights The projected fair value for Zhejiang Jingxin Pharmaceutical is CN¥12.16 based on 2 Stage Free Cash Flow to Equity Zhejiang Jingxin Pharmaceutical's CN¥11.36 share price indicates it is
Jingxin Pharmaceutical (002020.SZ): Net profit of 171 million yuan in the first quarter increased 13.23% year-on-year
Gelonghui, April 23 | Jingxin Pharmaceutical (002020.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,061 million yuan, up 10.44% year on year; net profit attributable to shareholders of listed companies was 171 million yuan, up 13.23% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 157 million yuan, up 14.30% year on year; basic earnings per share were 0.20 yuan.
Zhejiang Jingxin Pharmaceutical's (SZSE:002020) Problems Go Beyond Weak Profit
The subdued market reaction suggests that Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) recent earnings didn't contain any surprises. We think that investors are worried about some weakne
Jingxin Pharmaceutical (002020.SZ): Net profit in 2023 fell by 6.55% to 619 million yuan, plans to pay 10 to 3 yuan
Gelonghui March 29 | Jingxin Pharmaceutical (002020.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 3,999 billion yuan, up 5.79% year on year; net profit attributable to shareholders of listed companies was 619 million yuan, down 6.55% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 533 million yuan, down 11.60% year on year; basic income per share was 0.72 yuan; it plans to distribute a cash dividend of 3 yuan (tax included) for every 10 shares to all shareholders.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) Surges 7.2%; Retail Investors Who Own 40% Shares Profited Along With Insiders
Key Insights Zhejiang Jingxin Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 9 investors hav
Jingxin Pharmaceutical (002020.SZ): The administrative examination and approval of new drugs has come to an end
Gelonghui March 15 丨 An investor asked Jingxin Pharmaceutical (002020.SZ) on the investor interactive platform, “To what extent has the company's new drugs been marketed and sold? What else needs approval?” The company replied that the administrative review and approval process for the company's new drug has come to an end, so preparations are being made for marketing.
Jingxin Pharmaceutical (002020.SZ): The company's generic drugs and Jufeng's medical display module business both have CMO/ODM business
Gelonghui March 15 | Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company's generic drugs and Jufeng's medical display module business both have CMO/ODM business. The generic drug CMO business is mainly in the European market, and is currently expanding the domestic market; Jufeng's ODM customers are widely distributed, with important domestic customers such as Mindray and Lianying, as well as key overseas customers such as GE, Siemens, Philips, and Canon. Currently, this business has not been sanctioned.
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Jumps 5.8% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
While Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 24% in the la
Jingxin Pharmaceutical (002020.SZ): The company's current statin products include rosuvastatin, simvastatin, and pivastatin
Gelonghui, Feb. 6 | Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company's current statin products include rosuvastatin, simvastatin, and pivastatin. Rosuvastatin and simvastatin completed the domestic procurement renewal process in 2022. Simvastatin covered the whole country after renewal, and rosofastatin covered more than 25 provinces after renewal. Pivastatin will continue to work in 2023, and has now been selected by the Su-Shaanxi League. For specific data, please check the national collection website.
Could The Market Be Wrong About Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) Given Its Attractive Financial Prospects?
Zhejiang Jingxin Pharmaceutical (SZSE:002020) has had a rough three months with its share price down 18%. But if you pay close attention, you might gather that its strong financials could mean that
Jingxin Pharmaceutical (002020.SZ): Sales agent bidding for didacinib is in progress
Gelonghui January 25 | Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that trial production work at the company's Shandong base is being arranged in an orderly manner. For specific business conditions, please pay attention to subsequent regular reports. The bidding process for sales agents for Didacini is in progress and is not over yet.
Jingxin Pharmaceutical (002020.SZ): The company has neuropsychiatric, cardiovascular and digestive tract products that exceed 100 million yuan
Gelonghui, January 25 | Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company's mental, neurological, cardiovascular, and digestive tract products all exceed 100 million yuan. Marked by the launch of Gennonin, the company will balance the development of generic drugs and innovative drugs in the future.
Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) Share Price Is Matching Sentiment Around Its Earnings
Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) price-to-earnings (or "P/E") ratio of 15.7x might make it look like a strong buy right now compared to the market in China, where around half
Jingxin Pharmaceutical (002020.SZ): Didacinil R&D has invested about 200 million yuan
Gelonghui January 3 丨 Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that it has invested about 200 million yuan in research and development of didacinil. The company believes that Didacini has good commercial prospects and can bring good benefits to the company after commercialization.
Jingxin Pharmaceutical (002020.SZ): The company has no CDMO business
Gelonghui, January 3 | Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company's business activities are normal and orderly, and please pay attention to the company's regular reports on performance. The company does not yet have a CDMO business. Please refer to the company's regular report for the API planning status.
Analysis
Price Target
No Data
